Skip to main content

Table 3 Changes measured by OCT and ICGA in eyes at the 12-month follow-up

From: Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy

Number of eyes (%) Morphological changes
43 (60.6%) Subretinal fluids absorbed
39 (55.7%) PED resolved
15 (18.8%) Complete regression of polyps
22 (27.5%) Reduction in polyps
  1. OCT optical coherence tomography, ICGA indocyanine green angiography, PED pigment epithelial detachment